Who
Earl Martin Douglas
SVP, General Counsel
Company insider
Files Form 4 as: SVP, General Counsel, Allogene Therapeutics; General Counsel, Biomimetic Therapeutics.
In numbers
- Trades disclosed
- 74
- Buys
- 2
- Sells
- 19
- Bought
- $63K
- Sold
- $664K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 16 Jan 2007
- Last trade
- 21 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Aug 2026filed 25 Aug 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $63K29,697 at $2.12 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $63K29,697 at $2.12 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K22,900 at $1.76 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —539,072 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —152,480 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —539,072 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —152,480 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K22,900 at $1.76 | filing |
| 3 Feb 2025filed 5 Feb 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K6,404 at $1.71 | filing |
| 24 Jan 2025filed 28 Jan 2025 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —512,370 at $0.00 | filing |
| 24 Jan 2025filed 28 Jan 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —144,928 at $0.00 | filing |
| 21 Aug 2024filed 23 Aug 2024 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code F | $79K28,310 at $2.79 | filing |
| 25 Jan 2024filed 31 Jan 2024 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —147,778 at $0.00 | filing |
| 25 Jan 2024filed 31 Jan 2024 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —41,800 at $0.00 | filing |
| 14 Aug 2023filed 17 Aug 2023 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —960,854 at $0.00 | filing |
| 14 Aug 2023filed 17 Aug 2023 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —108,958 at $0.00 | filing |
| 14 Aug 2023filed 17 Aug 2023 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —326,876 at $0.00 | filing |
| 28 Mar 2012filed 28 Mar 2012 | Biomimetic Therapeutics | SEC FORM 4 Sold | $12K5,000 at $2.35 | filing |
| 28 Mar 2012filed 28 Mar 2012 | Biomimetic Therapeutics | SEC FORM 4 Sold | $2,5521,100 at $2.32 | filing |
| 28 Mar 2012filed 28 Mar 2012 | Biomimetic Therapeutics | SEC FORM 4 Sold | $466200 at $2.33 | filing |
News
Head to Head Analysis: Keros Therapeutics (NASDAQ:KROS) & Allogene Therapeutics (NASDAQ:ALLO)ALLO · tickerreport.com · 24 Oct 2026Comparing eXoZymes (NASDAQ:EXOZ) and Allogene Therapeutics (NASDAQ:ALLO)ALLO · dailypolitical.com · 16 Oct 2026
0 headlines in the last 90 days name Earl Martin Douglas; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.